---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-23-191394"
form_type: "8-K"
ticker: "CPRX"
cik: "0001369568"
company_name: "CATALYST PHARMACEUTICALS, INC."
filed_at: "2023-07-21T23:59:59+00:00"
generated_at: "2026-06-13T04:52:28.039314+00:00"
event_type: "m_and_a"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Catalyst completes $75M license for vamorolone, a DMD drug with PDUFA Oct 26, 2023

## Summary
- All-cash $75M license payment plus $15M equity investment for 11.26% stake in Santhera.
- Vamorolone has FDA Fast Track and Orphan Drug status; PDUFA action date Oct 26, 2023.
- Catalyst expects to launch vamorolone in the U.S. early Q1 2024, if approved.
- Minimal sales force expansion (<10 new reps) due to synergy with existing neuromuscular franchise.
- Catalyst will pay milestones and royalties on net sales; vamorolone rights cover U.S., Canada, Mexico.

## SEC filing metadata
- accession: 0001193125-23-191394
- form_type: 8-K
- ticker: CPRX
- cik: 0001369568
- company_name: CATALYST PHARMACEUTICALS, INC.
- filed_at: 2023-07-21T23:59:59+00:00
- event_type: m_and_a
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1369568/000119312523191394/0001193125-23-191394-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1369568/000119312523191394/d419142d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-23-191394
- JSON: https://secwatch.observer/filing/0001193125-23-191394.json
- Plain text: https://secwatch.observer/filing/0001193125-23-191394.txt

## Key facts
- M&A Transactions
  CATALYST PHARMACEUTICALS, INC. completed an acquisition involving Santhera Pharmaceuticals Holdings AG for all-cash purchase payment of $75 million; strategic equity investment of approximately $15 million in Santhera ordinary shares; potential milestone payments and (closed 2023-07-19).
  - Action: acquisition
  - Counterparty: Santhera Pharmaceuticals Holdings AG
  - Consideration: all-cash purchase payment of $75 million; strategic equity investment of approximately $15 million in Santhera ordinary shares; potential milestone payments and
  - Closing: 2023-07-19
  source text: Item 2.01 Completion of Acquisition or Disposition of Assets On July 19, 2023, Catalyst Pharmaceuticals, Inc. (the “ Company ”) completed its acquisition from Santhera Pharmaceuticals Holdings AG (“ Santhera ”) of an exclusive license for North America for vamorolone, a potential treatment for patients suffering with Duchenne Muscular Dystrophy (“ DMD ”). The license is for exclusive commercial rights in the U.S., Canada, and Mexico, as well as the right of first negotiation in Europe and Japan should Santhera pursue partnership opportunities. Additionally, the Company will hold North American rights for any future approved indications of vamorolone. As previously disclosed, the Company will make an all-cash purchase payment of $75 million to acquire the license pursuant to a License Agreement, dated June 19, 2023, by and between Santhera, its wholly owned subsidiary, Santhera Pharmaceuticals (Schweiz) AG, and the Company (the “ License Agreement ”). Simultaneously, pursuant to an Inve
  evidence_url: https://www.sec.gov/Archives/edgar/data/1369568/000119312523191394/0001193125-23-191394-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.